Sanofi Appoints Belén Garijo as CEO, Declares €4.12 Dividend, and Welcomes New Director

summarizeSummary

Sanofi's Annual General Meeting approved the appointment of Belén Garijo as the new CEO, effective May 1, 2026, alongside the declaration of a €4.12 annual dividend and the addition of Christel Heydemann to the board.

check_boxKey Events

• New Chief Executive Officer Appointed

  Belén Garijo was formally appointed as Director and Chief Executive Officer, effective May 1, 2026, following shareholder approval at the Annual General Meeting. Her mandate includes strengthening execution discipline and refining capital allocation.

• Annual Dividend Declared

  Shareholders approved an ordinary annual dividend of €4.12 per share, with payment scheduled for May 7, 2026.

• New Independent Director Joins Board

  Christel Heydemann, CEO of Orange, was appointed as an independent board member, bringing experience in Digital and AI technologies to the board.

auto_awesomeAnalysis

This filing signals a significant leadership transition and a commitment to shareholder returns for Sanofi. The appointment of Belén Garijo as CEO, effective May 1, 2026, brings a leader with a strong track record in R&D, strategy, and business transformation, with a mandate to strengthen execution and capital allocation. This decisive leadership change, coupled with the declaration of a substantial €4.12 annual dividend, may be aimed at reassuring investors and driving performance, especially as the company's stock is currently trading near its 52-week low. The addition of Christel Heydemann, CEO of Orange, as an independent board member further strengthens governance with expertise in digital and AI technologies.